Nateglinide

From Wikipedia, the free encyclopedia - View original article

Nateglinide
Nateglinide.svg
Systematic (IUPAC) name
3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
Clinical data
Trade namesStarlix
AHFS/Drugs.commonograph
MedlinePlusa699057
Licence dataEMA:Link, US FDA:link
Legal status
RoutesOral
Pharmacokinetic data
Protein binding98%
Half-life1.5 hours
Identifiers
CAS number105816-04-4 YesY
ATC codeA10BX03
PubChemCID 60026
DrugBankDB00731
ChemSpider10482084 YesY
UNII41X3PWK4O2 YesY
KEGGD01111 N
ChEBICHEBI:31897 N
ChEMBLCHEMBL286559 N
Chemical data
FormulaC19H27NO3 
Mol. mass317.423 g/mol
 N (what is this?)  (verify)
 
Jump to: navigation, search
Nateglinide
Nateglinide.svg
Systematic (IUPAC) name
3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
Clinical data
Trade namesStarlix
AHFS/Drugs.commonograph
MedlinePlusa699057
Licence dataEMA:Link, US FDA:link
Legal status
RoutesOral
Pharmacokinetic data
Protein binding98%
Half-life1.5 hours
Identifiers
CAS number105816-04-4 YesY
ATC codeA10BX03
PubChemCID 60026
DrugBankDB00731
ChemSpider10482084 YesY
UNII41X3PWK4O2 YesY
KEGGD01111 N
ChEBICHEBI:31897 N
ChEMBLCHEMBL286559 N
Chemical data
FormulaC19H27NO3 
Mol. mass317.423 g/mol
 N (what is this?)  (verify)

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Pharmacology[edit]

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Contraindications[edit]

Nateglinide is contraindicated in patients who:

Comparisons with other drugs for type 2 diabetes[edit]

A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial".[1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."

Dosage[edit]

Nateglinide is delivered in 60 mg & 120 mg tablet form.

References[edit]

  1. ^ Rosenstock, Julio Rosenstock; Hassman, David R.; Madder, Robert D.; Brazinsky, Shari A.; Farrell, James; Khutoryansky, Naum; Hale, Paula M. (June 2004), "Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study", Diabetes Care (American Diabetes Association) 27 (6): 1265–1270, retrieved 2014-11-20 

External links[edit]